The Time is Now: All ALS Therapies should be granted priority review

Health Canada recently began its review of AMX0035 to assess the therapy’s safety, efficacy, and quality. This process began in August when Health Canada accepted the manufacturer’s New Drug Submission (NDS). There are two timelines under which Health Canada conducts drug reviews: Standard Review, which is almost a one-year process (300 days) Priority Review, which […]

Can zebrafish help explain how mutations in this gene contribute to ALS?

An interdisciplinary Canadian team headed by Dr. Gary Armstrong of The Neuro (Montreal Neurological Institute-Hospital)  is poised to explore how a recently linked pair of genes contribute to the onset of ALS. In 2014, mutations in a gene called CHCHD10 were newly identified as a genetic cause of ALS; just four years later, Dr. Eric […]

Knowing the issues that matter to the ALS Community: ALS Election Commitments

The 2021 federal election is wrapping up in less than a week! With Election Day scheduled for Monday, September 20, 2021, now more than ever, it’s important to know the issues that matter to you before you cast your vote. ALS Canada reached out to each major political party to get more details about how […]